Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
NVCoV-2 by NanoViricides for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
NVCoV-2 is under clinical development by NanoViricides and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to...
Data Insights
NVCoV-2 by NanoViricides for Middle East Respiratory Syndrome (MERS): Likelihood of Approval
NVCoV-2 is under clinical development by NanoViricides and currently in Phase I for Middle East Respiratory Syndrome (MERS). According to...